ADP 600
Alternative Names: ADP-600Latest Information Update: 21 Mar 2024
At a glance
- Originator Adaptimmune
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Mar 2024 Adaptimmune plans to file patent for national and regional applications for T-cell therapy aimed at the PRAME target
- 20 Mar 2024 Adaptimmune files for PCT patent protection for T-cell therapy aimed at the PRAME target
- 24 Nov 2023 Preclinical trials in Cancer in United Kingdom (Parenteral) prior to November 2023 (Adaptimmune pipeline, November 2023)